Tregs inhibit the donor CD4+ and CD8+ T cells, leading to T cell loss of function and may reduce the expression of the molecule at the antigen presenting cell surface, which is required for T cell activation; thus, reducing graft versus host disease (GVHD) (13). Here, CD8A is linked to graft versus host disease.